Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWP63C)

• Drug Name: CD79-targeted immunotoxins Drug Info
• Synonyms: Anti-CD79b-MC-MMAF; Anti-CD79b-MCC-DM1; Anti-CD79b-vc-MMAE; Anti-CD79b-vc-vedotin; CD79-targeted immunotoxins (non-Hodgkin's lymphoma); CD79-targeted immunotoxins (non-Hodgkin's lymphoma), Genentech; Anti-CD79 antibody-drug conjugates (non-Hodgkin's lymphoma), Genentech

Indication

Disease Entry	ICD 11	Status	REF
Non-hodgkin lymphoma	2B33.5	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DMWP63C

Molecule-Related Drug Atlas

Drug(s) Targeting B-cell-specific glycoprotein B29 (CD79B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Polatuzumab vedotin	DMF6Y0L	Diffuse large B-cell lymphoma	2A81	Approved	[2]
RG7596	DMVXGU0	Haematological malignancy	2B33.Y	Phase 2	[1]
DCDS-4501A	DMQRCX5	Diffuse large B-cell lymphoma	2A81	Phase 2	[3]
Polivy	DMFCIKN	Mantle cell lymphoma	2A85.5	Phase 2	[4]
MGD010	DMA368V	Autoimmune disease	4A40-4A45	Phase 1	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell-specific glycoprotein B29 (CD79B)	TTBN5I7	CD79B_HUMAN	Not Available	[1]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2852).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.
• [4] Polatuzumab Vedotin: First Global Approval. Drugs. 2019 Sep;79(13):1467-1475.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)